Highlights

  • EVE Health Group (ASX:EVE) commenced a pilot clinical study evaluating its Libbo erectile dysfunction oral film.
  • The study compares Libbo vardenafil 10 mg film against an Australian-registered vardenafil tablet.
  • Results are expected in Q3'2026 and will guide the design of a future pivotal bioequivalence study.
  • Libbo forms part of EVE’s broader digital men’s health and pharmaceutical product strategy.

EVE Health Group (ASX:EVE) has moved its lead men’s health product, Libbo, into its first clinical study as the company progresses towards potential regulatory registration and commercialisation.

The pilot study represents an early clinical step focused on pharmacokinetics and tolerability rather than treatment efficacy. The outcome will determine the pathway for a larger bioequivalence study required to support future regulatory approval.

What Happened?

On 16 June 2026, EVE Health Group announced the commencement of a pilot pharmacokinetic study for Libbo, its vardenafil 10 mg oral soluble film product designed for erectile dysfunction treatment.

The study compares Libbo against an Australian-registered reference vardenafil tablet in healthy male volunteers under fasted conditions.

The trial includes tolerability assessments specific to the oral film format, with results expected in Q3'2026.

EVE described the study as a design-setting exercise to generate data required for a subsequent pivotal bioequivalence study.

Why It Matters

Libbo uses an established active pharmaceutical ingredient, vardenafil, rather than developing a new chemical entity.

This means the regulatory pathway focuses on demonstrating that the oral film delivers the active ingredient in a comparable manner to an approved tablet.

A successful pharmacokinetic and tolerability outcome could allow EVE to progress towards a larger bioequivalence study, which would form the basis of a future registration application.

The oral film format is designed to provide a discreet administration option without requiring water, targeting consumer preferences around convenience and privacy.

The Numbers

The disclosed clinical details include:

  • Libbo dosage: 10 mg vardenafil oral soluble film.
  • Comparator: Australian-registered vardenafil reference tablet.
  • Study population: healthy male volunteers under fasted conditions.
  • Expected results: Q3'2026.

EVE has not disclosed participant numbers, efficacy endpoints or Revenue forecasts for the pilot study.

The company has highlighted erectile dysfunction as a significant healthcare market, with prevalence estimates including approximately one in five adult men and higher rates among older male populations.

In October 2025, EVE raised A$1.1 million from sophisticated and professional investors to support commercial development of Libbo and another product, Dyspro.

The Bigger Picture

EVE Health is positioning Libbo as part of a broader men’s health platform rather than a standalone product.

The company is also developing additional products, including a reformulated dapoxetine product for premature ejaculation and a combination spray containing vardenafil and dapoxetine.

EVE’s commercial strategy includes combining pharmaceutical products with a digital healthcare platform involving patient education, clinical assessment and direct-to-patient delivery.

The company has referenced services including hubMed, TeleDocs Clinic and Chemist2U as part of its planned patient access model.

The Bull Case

The positive case for EVE Health Group (ASX:EVE) is based on advancing Libbo through a potentially shorter regulatory pathway using an established pharmaceutical ingredient.

A successful bioequivalence pathway could reduce development requirements compared with a new drug program.

The oral film format may provide differentiation through convenience and user experience in an established erectile dysfunction market.

A broader men’s health portfolio and digital distribution model could provide additional commercial opportunities if successfully implemented.

Risks Investors Should Understand

EVE Health Group (ASX:EVE)’s Business faces risks including clinical development uncertainty, regulatory requirements, commercial competition and funding needs.

A successful outcome from the pilot study is not guaranteed, and a reformulated delivery system may not demonstrate comparable pharmacokinetic performance to the reference tablet.

The erectile dysfunction market is competitive, with established generic treatments and digital healthcare providers competing for customers.

Building a vertically integrated digital healthcare platform requires additional resources and execution capability.

The company’s previous Capital raising provides funding support, but further funding may be required to complete clinical studies and commercial expansion.

What Comes Next?

The next major milestone is the Q3'2026 pilot study readout.

Investors will focus on pharmacokinetic and tolerability outcomes, followed by potential details on the design, timing and cost of a pivotal bioequivalence study.

Further updates on Dyspro, combination products and development of EVE’s digital healthcare platform will also be relevant.

Conclusion

EVE Health Group (ASX:EVE) has advanced Libbo into its first clinical study, establishing an important development milestone for its men’s health strategy.

The company is pursuing a regulatory pathway based on demonstrating equivalence with an existing erectile dysfunction medicine, which may reduce development complexity compared with a new drug program.

However, the pilot study is only the first step. Future progress depends on clinical results, regulatory approval, commercial adoption and the company’s ability to fund ongoing development activities.